A biomedical startup that focuses on implant technology and stem cell therapies has raised $7.4 million, according to a Securities and Exchange Commission filing. Vivex Biomedical Inc. is developing implant technology to help stimulate bone regrowth. Vivex has also licensed a highly adaptive adult stem cell line, known as MIAMI (Marrow Isolated Adult Multi-lineage Inducible) cells. With its implant and stem cell technology, Vivex plans to target patients with spinal cord injuries, orthopedic injuries and traumatic wounds.
Help employers find you! Check out all the jobs and post your resume.
